Loading
Caris Life Sciences' tissue test that reads every gene's DNA and RNA and stains for tumour proteins, offered outside the United States and Europe.
MI Profile is Caris Life Sciences' tissue profiling test for solid tumours. It combines whole-exome and whole-transcriptome sequencing of more than 23,000 genes with immunohistochemistry for more than 25 tumour proteins, and reports single-nucleotide variants, insertions and deletions, copy number changes, microsatellite instability and tumour mutational burden. Two AI signatures are added for particular cases: Caris GPSai for cancer of unknown primary and Caris FOLFIRSTai for metastatic colorectal cancer. Caris gives an average turnaround of 6 to 9 days from receipt of the sample. Caris states that MI Profile is available globally excluding the United States, the European Economic Area, the EU and Switzerland; its FDA-approved tissue test in the United States is MI Cancer Seek.
Whole-exome DNA and whole-transcriptome RNA sequencing of more than 23,000 genes from formalin-fixed tumour tissue, with immunohistochemistry for more than 25 tumour proteins and, for some tumour types, chromogenic in situ hybridisation, pyrosequencing and AI-based signatures.
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"MI Profile" OR ABSTRACT:"MI Profile" OR TITLE:"Caris MI Profile" OR ABSTRACT:"Caris MI Profile") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about MI Profile, not a curated reading list.
Shares H3 K27M mutation, MGMT promoter methylation, PDGFRA exon 18 mutation (D842V), BRAF fusion or rearrangement and the tag test.
Shares NRG1 gene fusion, NTRK1/2/3 gene fusion, Tumour mutational burden (TMB), Next-generation sequencing (NGS) and the tag test.
Shares BRAF fusion or rearrangement, FGFR3 alteration (mutation or fusion), FGFR2 fusion or rearrangement, MET exon 14 skipping mutation and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Immunohistochemistry (IHC), RNA sequencing & expression profiling and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), RNA sequencing & expression profiling, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR) and the tag test.
Shares PD-L1 CPS (combined positive score), Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR) and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), RNA sequencing & expression profiling, Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR) and the tag test.
Shares Tumour mutational burden (TMB), Next-generation sequencing (NGS), Microsatellite instability (MSI-H) / mismatch repair deficiency (dMMR), Comprehensive genomic profiling and the tag test.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/